{"id":"placebo-bai","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3907057","moleculeType":"Small molecule","molecularWeight":"558.54"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo, this agent contains no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo response—a psychobiological phenomenon where patient expectation and clinical context influence symptom perception and outcomes. Placebo BAI is used as a control comparator in clinical trials to distinguish true drug efficacy from placebo effects.","oneSentence":"Placebo BAI is an inert substance with no active pharmacological mechanism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:37.376Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clinical trial control comparator (not a therapeutic indication)"}]},"trialDetails":[{"nctId":"NCT04484818","phase":"PHASE3","title":"Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-03-01","conditions":"Prostate Carcinoma","enrollment":27},{"nctId":"NCT05958342","phase":"PHASE2","title":"CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial","status":"RECRUITING","sponsor":"Jason Sperry","startDate":"2024-06-30","conditions":"Trauma, Hemorrhage","enrollment":1050},{"nctId":"NCT00939627","phase":"PHASE2","title":"Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-07","conditions":"Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer","enrollment":55},{"nctId":"NCT06408246","phase":"PHASE2","title":"ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression","status":"RECRUITING","sponsor":"Stanford University","startDate":"2026-03-03","conditions":"Depression","enrollment":162},{"nctId":"NCT07397026","phase":"PHASE1","title":"Clinical and Laboratory Evaluation of Resveratrol Loaded Nanoparticles in the Treatment of Periodontitis: A Randomized Controlled Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hagar Ahmed Ali Mohammed Elzain","startDate":"2025-08-09","conditions":"Periodontitis Stage III","enrollment":48},{"nctId":"NCT06149520","phase":"PHASE2","title":"A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-01-15","conditions":"Thrombolysis, Symptomatic Proximal Deep Vein Thrombosis","enrollment":258},{"nctId":"NCT06736691","phase":"PHASE3","title":"Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections","status":"ENROLLING_BY_INVITATION","sponsor":"Swiss Tropical & Public Health Institute","startDate":"2025-11-25","conditions":"Trichuris Trichiura; Infection, Hookworm Infection, Ascaris Lumbricoides Infection","enrollment":315},{"nctId":"NCT06800248","phase":"PHASE3","title":"Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections","status":"NOT_YET_RECRUITING","sponsor":"Swiss Tropical & Public Health Institute","startDate":"2026-04","conditions":"Trichuris Trichiura; Infection, Hookworm Infection, Ascaris Lumbricoides Infection","enrollment":315},{"nctId":"NCT07176728","phase":"PHASE1","title":"A Study to Assess the Safety and Effects of Different Doses of an Investigational Drug, BAY 3389934, in Healthy Japanese Volunteers.","status":"RECRUITING","sponsor":"Bayer","startDate":"2025-09-22","conditions":"Sepsis Associated Disseminated Intravascular Coagulation (DIC)","enrollment":16},{"nctId":"NCT05093933","phase":"PHASE3","title":"A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-11-02","conditions":"Chronic Heart Failure With Reduced Ejection Fraction","enrollment":6106},{"nctId":"NCT07091084","phase":"NA","title":"A Study of Herbal Supplements in Cancer Survivors With Constipation","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-07-15","conditions":"Constipation, Cancer, Functional Constipation","enrollment":70},{"nctId":"NCT02799602","phase":"PHASE3","title":"Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-11-30","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":1306},{"nctId":"NCT07161102","phase":"NA","title":"Effect of Foot Reflexology on Anxiety","status":"ENROLLING_BY_INVITATION","sponsor":"Carlos Germano Dias Santos","startDate":"2025-07-30","conditions":"Anxiety Disorders","enrollment":44},{"nctId":"NCT04686955","phase":"PHASE3","title":"The Efficacy of Patients With Moderate to Severe Atopic Dermatitis Treated With Chinese Herbal Medicine","status":"COMPLETED","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2021-01-25","conditions":"Atopic Dermatitis","enrollment":19},{"nctId":"NCT05686070","phase":"PHASE3","title":"A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-01-26","conditions":"Prevention of Ischemic Stroke, Acute Non-cardioembolic Ischemic Stroke, High-risk Transient Ischemic Attack","enrollment":12327},{"nctId":"NCT07211685","phase":"PHASE2","title":"BAY3401016; Biomarker Study Alport","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2025-12-02","conditions":"Alport Syndrome","enrollment":60},{"nctId":"NCT06522997","phase":"PHASE2","title":"A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2024-08-08","conditions":"Chronic Kidney Disease","enrollment":700},{"nctId":"NCT07181135","phase":"PHASE3","title":"FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2025-12-01","conditions":"Chronic Kidney Disease","enrollment":180},{"nctId":"NCT07145060","phase":"NA","title":"A Study of Yiqi Yangyin Formula in the Treatment of Primary Sjogren's Syndrome","status":"NOT_YET_RECRUITING","sponsor":"China-Japan Friendship Hospital","startDate":"2025-09-01","conditions":"Primary Sjögren's Syndrome (pSS)","enrollment":105},{"nctId":"NCT01065454","phase":"PHASE2","title":"A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-04-14","conditions":"Hypertension, Pulmonary, Ventricular Dysfunction, Left","enrollment":202},{"nctId":"NCT07026539","phase":"PHASE4","title":"Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes.","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2024-10-23","conditions":"Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease Due to Type 2 Diabetes Mellitus, Cardiovascular Diseases","enrollment":80},{"nctId":"NCT06048120","phase":"PHASE1","title":"A Study to Learn How Safe the Study Treatment BAY2701250 is, How it Affects the Body and How it Moves Into, Through and Out of the Body in Healthy Male Participants When a Single Amount is Given as an Injection Into the Vein (Intravenous Infusion) or Under the Skin (Subcutaneous Injection)","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-09-15","conditions":"Pulmonary Hypertension Due to Left Heart Disease","enrollment":82},{"nctId":"NCT04722991","phase":"PHASE2","title":"Non-proliferative Diabetic Retinopathy Treated With Runcaciguat","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-03-17","conditions":"Diabetic Retinopathy","enrollment":109},{"nctId":"NCT05656911","phase":"PHASE2","title":"A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-12-21","conditions":"Atopic Dermatitis","enrollment":77},{"nctId":"NCT06619483","phase":"PHASE1","title":"A Study to Learn How Safe BAY3018250 is, How it Moves Into, Through and Out of the Body, and How it Affects the Body in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-10-10","conditions":"Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers","enrollment":24},{"nctId":"NCT06562985","phase":"PHASE1","title":"A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-09-18","conditions":"Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers","enrollment":39},{"nctId":"NCT05643573","phase":"PHASE3","title":"A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke","status":"TERMINATED","sponsor":"Bayer","startDate":"2022-12-05","conditions":"Prevention of Stroke or Systemic Embolism, Atrial Fibrillation","enrollment":14830},{"nctId":"NCT05670912","phase":"PHASE2","title":"Efficacy and Safety of Wei Li Bai Capsules in the Treatment of Alzheimer's Disease","status":"TERMINATED","sponsor":"Capital Medical University","startDate":"2022-10-01","conditions":"Alzheimer Disease","enrollment":105},{"nctId":"NCT06474208","phase":"PHASE1","title":"A Study to Learn About the Taste of Vericiguat Given in Liquid Form in Healthy Male Participants Aged 18 to 45 Years","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-07-01","conditions":"Heart Failure","enrollment":19},{"nctId":"NCT06487845","phase":"PHASE1","title":"A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-07-04","conditions":"Chronic Kidney Disease, Non-proliferative Diabetic Retinopathy, Healthy Volunteers","enrollment":24},{"nctId":"NCT06511973","phase":"PHASE1","title":"A Study to Learn About Whether BAYH006689 Causes Skin Irritation When Applied as a Topical Gel in Healthy Participants","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-07-23","conditions":"Pain, Healthy Volunteers","enrollment":42},{"nctId":"NCT06415019","phase":"PHASE1","title":"A Study to Learn About Whether BAY H006689 Causes an Allergic Reaction When Applied as a Topical Gel in Healthy Participants","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-06-05","conditions":"Pain, Healthy Volunteers","enrollment":236},{"nctId":"NCT05750446","phase":"NA","title":"Effect of Riocigaut on Migraine Attack Induction in People With Migraine","status":"COMPLETED","sponsor":"Danish Headache Center","startDate":"2023-06-01","conditions":"Migraine Without Aura","enrollment":22},{"nctId":"NCT06381960","phase":"PHASE2","title":"Clinical Study on the Prevention and Treatment of Postoperative Metastasis of Lung Cancer by Fuzheng Quxie Recipe","status":"RECRUITING","sponsor":"Jianhui Tian","startDate":"2023-03-01","conditions":"Lung Cancer","enrollment":356},{"nctId":"NCT05532046","phase":"PHASE1","title":"A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT)","status":"TERMINATED","sponsor":"Bayer","startDate":"2022-09-20","conditions":"Chronic Heart Failure","enrollment":22},{"nctId":"NCT05180461","phase":"PHASE2","title":"Emodepside Phase II Trial for Treatment of Onchocerciasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Drugs for Neglected Diseases","startDate":"2021-08-30","conditions":"Onchocerciasis","enrollment":578},{"nctId":"NCT04859660","phase":"PHASE2","title":"Pre-operative Tamsulosin and Time to Spontaneous Void After Hysterectomy","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2021-04-16","conditions":"Urinary Retention Postoperative","enrollment":161},{"nctId":"NCT05582811","phase":"NA","title":"Effect of Riocigaut on Cerebral Vasodilation and Headache Induction in Healthy Volunteers","status":"COMPLETED","sponsor":"Danish Headache Center","startDate":"2022-10-26","conditions":"Headache","enrollment":15},{"nctId":"NCT01004978","phase":"PHASE3","title":"Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-10-28","conditions":"Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma","enrollment":235},{"nctId":"NCT01624285","phase":"PHASE2","title":"Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2012-07-16","conditions":"Adult Primary Hepatocellular Carcinoma, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer","enrollment":20},{"nctId":"NCT00606866","phase":"PHASE3","title":"MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2004-07","conditions":"Metastatic Renal Cell Carcinoma","enrollment":57},{"nctId":"NCT06135181","phase":"PHASE1","title":"A Study to Learn More About the Safety and the Blood Level of BAY1747846 Given as Injection Into the Vein at Increasing Single Doses in Chinese Healthy Male Participants","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-08-26","conditions":"Contrast Enhancement in Magnetic Resonance Imaging, Healthy Volunteers","enrollment":24},{"nctId":"NCT02369016","phase":"PHASE3","title":"Phase III Copanlisib in Rituximab-refractory iNHL","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-09-22","conditions":"Lymphoma, Non-Hodgkin","enrollment":25},{"nctId":"NCT05219812","phase":"PHASE2","title":"A Study to Learn How Safe BAY2395840 is and How Well it Works in Participants Who Have Diabetic Nerve Pain","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-02-16","conditions":"Neuropathic Pain Associated With Diabetic Peripheral Neuropathy, Peripheral Neuropathic Pain, Diabetes Mellitus","enrollment":80},{"nctId":"NCT06125366","phase":"PHASE1","title":"A Study to Learn More About the Safety and the Level of BAY 1747846 in Body Given as Injection Into the Vein at Increasing Single Doses in Japanese Healthy Male Participants","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-04-17","conditions":"Contrast Enhancement in Magnetic Resonance Imaging, Healthy Volunteers","enrollment":25},{"nctId":"NCT05698550","phase":"PHASE3","title":"The Role of Erzhi Tiangui Formula in Expected POR Women Undergoing IVF-ET","status":"UNKNOWN","sponsor":"Shandong University of Traditional Chinese Medicine","startDate":"2023-09-15","conditions":"Infertility, Female","enrollment":480},{"nctId":"NCT05800444","phase":"PHASE1","title":"A Study to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body, How it Moves Into, Through and Out of the Body When Single and Multiple Amounts Are Taken as Tablets in Japanese Healthy Male Participants","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-04-03","conditions":"Chronic Kidney Disease, Healthy Volunteers","enrollment":24},{"nctId":"NCT04508023","phase":"PHASE3","title":"A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-08-13","conditions":"Coronavirus Disease 2019 (COVID-19)","enrollment":1284},{"nctId":"NCT04534114","phase":"PHASE2","title":"Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-09-04","conditions":"End Stage Renal Disease Requiring Hemodialysis","enrollment":307},{"nctId":"NCT00064350","phase":"PHASE2","title":"Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2004-06-28","conditions":"Lung Cancer","enrollment":342},{"nctId":"NCT02066181","phase":"PHASE3","title":"Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-03-21","conditions":"Desmoid Fibromatosis","enrollment":87},{"nctId":"NCT02868671","phase":"NA","title":"Acupuncture for Mild Traumatic Brain Injury：A Functional Magnetic Resonance Imaging Study","status":"COMPLETED","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2016-08","conditions":"Acupuncture, Mild Traumatic Brain Injury, MRI","enrollment":66},{"nctId":"NCT05491642","phase":"PHASE1","title":"A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-09-08","conditions":"Chronic Kidney Disease, Hypertension","enrollment":56},{"nctId":"NCT04304508","phase":"PHASE2","title":"Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-06-15","conditions":"Acute Non-cardioembolic Ischemic Stroke","enrollment":1808},{"nctId":"NCT04304534","phase":"PHASE2","title":"Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-06-17","conditions":"Acute Myocardial Infarction","enrollment":1601},{"nctId":"NCT04507061","phase":"PHASE2","title":"Study on the Safety of the Drug Runcaciguat and How Well it Works When Given at the Highest Dose as Tolerated by Individual Patient Whose Kidneys Are Not Working Properly and Suffering at the Same Time From High Blood Sugar and/or High Blood Pressure and a Disease of the Heart and the Blood Vessels.","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-09-01","conditions":"Chronic Kidney Disease","enrollment":243},{"nctId":"NCT05563454","phase":"PHASE1","title":"A Study to Learn How Safe the Study Treatment BAY2395840 is, How it Affects the Body and How it Moves Into, Through, and Out of the Body if Given in Single and in Repetitive Doses to Japanese Healthy Male Participants","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-10-11","conditions":"Diabetic Neuropathic Pain, Healthy Volunteers","enrollment":24},{"nctId":"NCT02490813","phase":"NA","title":"Pilot Study on Traditional Chinese Medicine and Food Allergy","status":"TERMINATED","sponsor":"Hong Kong Sanatorium & Hospital","startDate":"2015-06-18","conditions":"Allergy to Fish, Allergy to Shrimp, Allergy to Crab","enrollment":18},{"nctId":"NCT04872387","phase":"PHASE1","title":"A Study to Learn More About How Safe BAY2586116 is, How it Affects the Body, How it Moves Into, Through and Out of the Body at Different Doses in Healthy Japanese Male Participants After Taking Single and Multiple Doses Through the Nose","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-05-11","conditions":"Obstructive Sleep Apnea","enrollment":36},{"nctId":"NCT04265781","phase":"PHASE1","title":"Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-02-15","conditions":"Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain","enrollment":36},{"nctId":"NCT04487431","phase":"PHASE1","title":"A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B)","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-08-05","conditions":"Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain","enrollment":14},{"nctId":"NCT03310645","phase":"PHASE1, PHASE2","title":"Repeat Doses of BAY 1817080 in Healthy Males & Proof of Concept in Chronic Cough Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-12-07","conditions":"Cough","enrollment":87},{"nctId":"NCT04545580","phase":"PHASE2","title":"Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-09-16","conditions":"Overactive Bladder","enrollment":99},{"nctId":"NCT05003089","phase":"PHASE1","title":"A Trial to Learn How BAY1834845 and BAY1830839 Affect Inflammation When Taken by Mouth Twice a Day for 7 Days in a Row in Healthy Male Participants","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-06-28","conditions":"Immune Mediated Inflammatory Diseases","enrollment":51},{"nctId":"NCT04641273","phase":"PHASE2","title":"A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain","status":"TERMINATED","sponsor":"Bayer","startDate":"2021-01-22","conditions":"Neuropathic Pain Associated With Diabetic Peripheral Neuropathy","enrollment":154},{"nctId":"NCT04218266","phase":"PHASE2","title":"Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-01-30","conditions":"Atrial Fibrillation (AF)","enrollment":755},{"nctId":"NCT04713826","phase":"PHASE2","title":"A Trial to Learn More About How Well BAY2586116 Works and How Safe it is in Participants With Moderate to Severe Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-03-03","conditions":"Sleep Apnea, Obstructive","enrollment":93},{"nctId":"NCT04802343","phase":"PHASE1","title":"A Trial to Learn How BAY1817080 Moves Into, Through and Out of the Body and How Safe it is in Healthy Chinese Men","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-04-02","conditions":"Healthy Volunteers","enrollment":39},{"nctId":"NCT03580317","phase":"NA","title":"Electroacupuncture Therapy for Change of Pain in Classical Trigeminal Neuralgia","status":"COMPLETED","sponsor":"Zhejiang Chinese Medical University","startDate":"2018-07-12","conditions":"Trigeminal Neuralgia","enrollment":120},{"nctId":"NCT05517746","phase":"PHASE1","title":"Study on the Safety of the Drug BAY2395840 at Different Doses, the Way the Body Absorbs, Distributes and Excretes the Drug Including the Effect of Its Formulation (Tablet or Liquid) and the Effect of Food on the Absorption, Distribution or Excretion of the Drug in Healthy Male Participants","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-12-18","conditions":"Endometriosis","enrollment":63},{"nctId":"NCT04552262","phase":"PHASE1","title":"Study to Learn More About the Effect of a New Drug Called BAY2327949 on the Blood Flow Through Kidneys in Adult Participants With Moderate Chronic Kidney Disease","status":"TERMINATED","sponsor":"Bayer","startDate":"2020-09-30","conditions":"Moderate Chronic Kidney Disease","enrollment":7},{"nctId":"NCT04562155","phase":"PHASE2","title":"Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-10-02","conditions":"Refractory and/or Unexplained Chronic Cough","enrollment":310},{"nctId":"NCT04236440","phase":"PHASE2","title":"Study on the Safety of Drug BAY2586116 and How it Works in Patients With Obstructive Sleep Apnea (a Sleep Disorder Caused by the Narrowing and Collapse of the Airway During Sleep) Including the Blood Level of the Drug and Effect of Its Doses and Routes of Administration","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-02-04","conditions":"Sleep Apnea, Obstructive","enrollment":14},{"nctId":"NCT04851483","phase":"PHASE1","title":"A Trial to Learn What Happens to Different Medicinal Forms of BAY2328065 When They Enter the Body and How Safe They Are in Healthy Male and Female Participants","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-04-28","conditions":"Endometriosis","enrollment":31},{"nctId":"NCT03901729","phase":"PHASE2","title":"A Trial to Study BAY1753011 in Patients With Congestive Heart Failure","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-05-29","conditions":"Heart Failure (HF)","enrollment":482},{"nctId":"NCT00308685","phase":"PHASE3","title":"Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2006-06-10","conditions":"Asthma","enrollment":95},{"nctId":"NCT03412006","phase":"PHASE2","title":"A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-02-02","conditions":"Diabetic Kidney Disease","enrollment":152},{"nctId":"NCT01473108","phase":"PHASE1","title":"Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-03-29","conditions":"Clinical Pharmacology","enrollment":67},{"nctId":"NCT00326898","phase":"PHASE3","title":"Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-04-24","conditions":"Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7, Stage II Renal Cell Cancer AJCC v7","enrollment":1943},{"nctId":"NCT04423744","phase":"PHASE1","title":"Study to Gather Information on the Influence of BAY1817080 on the Electrical Activity of the Heart Recorded by an Electrocardiogram in Healthy Male and Female Participants","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-06-18","conditions":"Cough, Endometriosis, Overactive Bladder","enrollment":42},{"nctId":"NCT05204758","phase":"PHASE3","title":"Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect","status":"COMPLETED","sponsor":"China Medical University Hospital","startDate":"2016-05-12","conditions":"Advanced Lung Adenocarcinoma","enrollment":30},{"nctId":"NCT02617550","phase":"PHASE1","title":"Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-11-18","conditions":"Coronary Artery Disease","enrollment":36},{"nctId":"NCT02031640","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":"Asthma","enrollment":1113},{"nctId":"NCT02040779","phase":"PHASE3","title":"A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12-26","conditions":"Persistent Asthma","enrollment":273},{"nctId":"NCT02203474","phase":"PHASE2","title":"A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease","status":"WITHDRAWN","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-08","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":""},{"nctId":"NCT02040766","phase":"PHASE3","title":"A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-12","conditions":"Asthma","enrollment":628},{"nctId":"NCT02513160","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-09-30","conditions":"Persistent Asthma","enrollment":713},{"nctId":"NCT01968668","phase":"PHASE2","title":"Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-10-28","conditions":"Diabetic Nephropathies","enrollment":96},{"nctId":"NCT04950738","phase":"NA","title":"The Effectiveness of Acupuncture for Complications in Critically Ill Patients","status":"UNKNOWN","sponsor":"China Medical University Hospital","startDate":"2021-08-01","conditions":"Delirium, Agitation, Arrhythmia","enrollment":80},{"nctId":"NCT03273257","phase":"PHASE2","title":"Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)","status":"TERMINATED","sponsor":"International CTEPH Association","startDate":"2018-08-17","conditions":"Chronic Thromboembolic Pulmonary Hypertension, CTEPH","enrollment":14},{"nctId":"NCT04661917","phase":"PHASE2","title":"A Trial to Learn More About How BAY2327949 Works and How Safe it is in Patients Whose Kidneys Are Damaged Due to High Blood Sugar Levels or High Blood Pressures, and With a Further Disease of the Heart or the Blood Vessels.","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2021-05-31","conditions":"Chronic Kidney Disease, Diabetic Kidney Disease","enrollment":""},{"nctId":"NCT03025152","phase":"NA","title":"Efficacy and Safety of Hou Gu Mi Xi in Patients With Spleen Qi Deficiency and Radical Gastrectomy for Gastric Cancer","status":"TERMINATED","sponsor":"Jiangxi University of Traditional Chinese Medicine","startDate":"2016-11-11","conditions":"Gastric Cancer, Gastrointestinal Disease","enrollment":130},{"nctId":"NCT01298570","phase":"PHASE2","title":"Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2011-04-07","conditions":"Colorectal Cancer Metastatic","enrollment":181},{"nctId":"NCT03019042","phase":"NA","title":"Efficacy and Safety of Hou Gu Mi Xi in Patients With Spleen Qi Deficiency and Non-organic Gastrointestinal Disorders","status":"COMPLETED","sponsor":"Jiangxi University of Traditional Chinese Medicine","startDate":"2016-11-15","conditions":"Gastrointestinal Disease","enrollment":200},{"nctId":"NCT03383614","phase":"PHASE1","title":"Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2017-11-14","conditions":"Filariasis","enrollment":24},{"nctId":"NCT02661178","phase":"PHASE1","title":"First in Man Clinical Trial of Emodepside (BAY 44-4400)","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2015-12","conditions":"Healthy Volunteers","enrollment":79},{"nctId":"NCT02976467","phase":"PHASE2","title":"A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-12-30","conditions":"Myocardial Infarction","enrollment":107},{"nctId":"NCT03252002","phase":"PHASE1","title":"Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single and Multiple Oral BAY1101042 Tablet Doses in Healthy Male Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-08-16","conditions":"Healthy Volunteer","enrollment":96},{"nctId":"NCT02752880","phase":"PHASE2, PHASE3","title":"YH1 in Poorly Controlled Type 2 Diabetes","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2016-06","conditions":"Type 2 Diabetes","enrollment":46},{"nctId":"NCT02040233","phase":"PHASE2","title":"Multiple Dose Study in Heart Failure of BAY 1067197","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-01-28","conditions":"Heart Failure","enrollment":31}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["breath-actuated inhaler"],"phase":"phase_3","status":"active","brandName":"Placebo BAI","genericName":"Placebo BAI","companyName":"Teva Branded Pharmaceutical Products R&D, Inc.","companyId":"teva-branded-pharmaceutical-products-r-d-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo BAI is an inert substance with no active pharmacological mechanism. Used for Clinical trial control comparator (not a therapeutic indication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}